Houston, TX Clinical Trials Report — April 2026

For Houstonians considering participation in clinical research, April 2026 presents a critical window to join studies before enrollment concludes. Across Houston, a significant number of trials are nearing their closing dates, offering immediate opportunities for those ready to contribute to medical advancements. Specifically, 193 clinical trials are slated to close within the next 90 days. This urgency is particularly relevant for healthy volunteers, as 22 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Act Now: Trials Closing Soon

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on various cancers, metabolic disorders, and blood conditions are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Advanced solid tumor (5 trials)
• Myelodysplastic syndromes (4 trials)
• Acute myeloid leukemia (4 trials)
• Non-small cell lung cancer (4 trials)
• Obesity (3 trials)
• Triple negative breast cancer (3 trials)
• Ovarian cancer (3 trials)
• Metastatic cancer (3 trials)
• Metastatic malignant solid neoplasm (3 trials)

If you or someone you know is affected by these conditions, exploring these opportunities promptly is advisable.

New Opportunities in Houston Research

This month, Houston saw the opening of 18 new clinical trials. This marks a decrease from the 25 trials that launched in March 2026, and is part of a broader trend showing 18 new trials this month compared to 34 in March, 59 in February, 36 in January, 59 in December 2025, and 44 in November 2025. Despite this dip, the city continues to be a vibrant hub for medical research, with a total of 2,826 clinical trials currently recruiting across 1,028 research facilities.

April brings several notable new trials to Houston, including significant Phase 2 and Phase 3 studies from major sponsors. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges:

• Novo Nordisk A/S is sponsoring NCT07533175, a Phase 3 study titled "AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight." This trial aims for 630 participants to evaluate the safety and effectiveness of a new weekly injectable treatment.
• Incyte Corporation is launching NCT07522073, "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma." This important Phase 3 oncology trial seeks 588 participants to evaluate the efficacy and safety of a new combination therapy.
• Kinaset Therapeutics Inc is initiating NCT07532265, "A Phase 2 Dose Ranging Clinical Study to Evaluate the Efficacy and Safety of Frevecitinib (KN-002) in Patients With Severe Asthma." This study is designed for 512 participants who have severe asthma not controlled with standard treatments.
• Praxis Precision Medicines is sponsoring NCT07505004, "Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures." This Phase 3 study aims for 300 participants to assess a new treatment for focal seizures.
• M.D. Anderson Cancer Center is leading NCT07508995, "A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)." This study seeks 40 participants to assess a new time-limited treatment approach.
• The University of Texas Health Science Center, Houston is sponsoring NCT07525076, "Implementation of an Opt-Out Testing and Rapid Diagnostic Strategy for Syphilis and HIV in Pregnant Patients Presenting to the Emergency Department." This study aims for 1,400 participants to evaluate rapid diagnostic strategies.

Diverse Research Areas and Sponsors

New trials this month are exploring a range of conditions, including acute myeloid leukemia (AML), atypical teratoid rhabdoid tumor, cell carcinoma of the anus/rectum, central nervous system rhabdoid tumor, chronic lymphocytic leukemia (CLL), chronic stroke, diabetes mellitus, focal epilepsy, and metastatic gastric cancer. The majority of new studies are drug trials, with 13 new drug trials, followed by 3 "OTHER" type trials, 1 biological trial, and 1 diagnostic test trial.

Academic and institutional sponsors are driving much of the new research, with 13 new trials, while industry sponsors account for 5 new trials. Major sponsors include M.D. Anderson Cancer Center (9 trials), Baylor College of Medicine (2 trials), Incyte Corporation (1 trial), Kinaset Therapeutics Inc (1 trial), Immunome, Inc. (1 trial), Novo Nordisk A/S (1 trial), Praxis Precision Medicines (1 trial), and The University of Texas Health Science Center, Houston (1 trial).

Houston's Leading Research Institutions

Houston is home to some of the nation's leading research institutions, which consistently run a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• MD Anderson Cancer Center (393 trials)
• M D Anderson Cancer Center (351 trials)
• Baylor College of Medicine (176 trials)
• The University of Texas MD Anderson Cancer Center (137 trials)
• The University of Texas Health Science Center at Houston (126 trials)
• Houston Methodist Hospital (121 trials)
• Texas Children's Hospital (105 trials)
• University of Texas MD Anderson Cancer Center (89 trials)
• Research Site (81 trials)
• Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (66 trials)
• The University of Texas M. D. Anderson Cancer Center (64 trials)
• MD Anderson (42 trials)

These institutions, particularly the various branches of MD Anderson Cancer Center and Baylor College of Medicine, offer a broad spectrum of research, from oncology to pediatric care and general medical fields, making Houston a prominent center for clinical innovation.

Expanding Your Search: Nearby Texas Cities

While Houston offers a vast array of clinical trial opportunities, individuals may also find options in nearby communities within Texas. Cities with active trials include Dallas (9 trials), San Antonio (8 trials), Fort Worth (4 trials), Austin (3 trials), Galveston (2 trials), Plano (2 trials), Irving (1 trial), and Katy (1 trial).

Who Can Participate?

Participation in clinical trials is open to a diverse range of individuals. Of the 18 new trials launched this month, 14 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 4 new trials are specifically designed for children, 1 is female-only, and 1 is male-only. For individuals without a specific medical condition, there are significant opportunities to contribute; 2 of the new trials launched this month are actively seeking healthy volunteers, and a total of 194 trials are currently recruiting healthy participants across Houston.

As we move further into spring, Houston's robust research community will continue to drive medical innovation, with ongoing enrollment in significant Phase 2 and Phase 3 trials and the exploration of new therapeutic strategies across a wide range of health conditions.